Complementary and alternative medicines in the treatment of dementia - An evidence-based review

被引:22
作者
Diamond, BJ
Johnson, SK
Torsney, K
Morodan, J
Prokop, BJ
Davidek, D
Kramer, P
机构
[1] William Paterson Univ, Dept Psychol, Wayne, NJ USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA
[3] Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA
关键词
D O I
10.2165/00002512-200320130-00003
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Alternative medicines may have potential beneficial results in treating certain forms of dementia and related symptoms, as well as slowing disease progression. Alternative medicines may ameliorate disturbances in cognition, mood, sleep and activities of daily living. Primary mechanisms of action include modifications in neurotransmitter synthesis, inhibition of neurotransmitter reuptake and enzyme-induced neurotransmitter breakdown, antioxidant and anti-platelet activity, enhanced blood flow and glucose metabolism. Adverse events can include cardiovascular, gastrointestinal, mood, autonomic and dermatologic effects. However, adverse events, when reported represent, a small percentage of treated groups and direct links between adverse events and alternative therapies are tenuous. Many studies of alternative medicines in dementia are inconclusive and characterised by methodological deficiencies such as small sample sizes and inadequate controls. If alternative medicines can be shown to be efficacious using more rigourous experimental designs, both consumers and clinicians could avail themselves of a wider range of pharmacological substances that may offer the advantage of being better tolerated and exhibiting safer therapeutic margins than some allopathic medicines. While a number of complementary interventions have shown both strengths and weaknesses, huperzine A, levacecarnine and EGB 761, based on the overall quality of the studies, identified mechanisms of activity and safety profiles merit further examination in controlled clinical outcome studies.
引用
收藏
页码:981 / 998
页数:18
相关论文
共 118 条
[11]  
Brown R.P., 2000, CLIN PRACT INTERN ME, V1, P230
[12]  
Bruchert E, 1991, MUNCHENER MEDIZINISC, V133, pS9
[13]   Monozygotic twins with Alzheimer's disease treated with melatonin:: case report [J].
Brusco, LI ;
Márquez, M ;
Cardinali, DP .
JOURNAL OF PINEAL RESEARCH, 1998, 25 (04) :260-263
[14]  
Brusco LI, 1998, NEUROENDOCRINOL LETT, V19, P111
[15]   ACTION OF ACETYL-L-CARNITINE IN NEURODEGENERATION AND ALZHEIMERS-DISEASE [J].
CALVANI, M ;
CARTA, A ;
CARUSO, G ;
BENEDETTI, N ;
IANNUCCELLI, M .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1992, 663 :483-486
[16]  
Cardinali DP, 2002, NEUROENDOCRINOL LETT, V23, P20
[17]  
CARTA A, 1991, ANN NY ACAD SCI, V640, P228
[18]  
Cauffield J S, 1999, Lippincotts Prim Care Pract, V3, P290
[19]   TACRINE (TETRAHYDROAMINOACRIDINE - THA) AND LECITHIN IN SENILE DEMENTIA OF THE ALZHEIMER TYPE - A MULTICENTER TRIAL [J].
CHATELLIER, G ;
LACOMBLEZ, L .
BRITISH MEDICAL JOURNAL, 1990, 300 (6723) :495-499
[20]  
COEFFLER E, 1988, GINKGOLIDE, P105